Lanifibranor

Over 80 companies are actively developing treatments for Non-Alcoholic Steatohepatitis (NASH), with Inventiva Pharma and Cirius Therapeutics leading with Phase III candidates lanifibranor and MSDC-0602K respectively.

Inventiva and Hepalys Pharma have initiated the clinical development of lanifibranor in Japan, dosing the first participant in a Phase 1 trial to evaluate safety, tolerability, and pharmacokinetics.

Inventiva announces major restructuring, including significant workforce reduction and termination of preclinical programs, to extend financial runway through critical Phase III trial completion.

French biotech Inventiva announces major restructuring, planning to lay off 50% of employees and discontinue all preclinical research except for its lead MASH candidate lanifibranor.

Inventiva announces strategic pipeline prioritization, halting all preclinical research to focus exclusively on lanifibranor development for MASH treatment, with planned 50% workforce reduction.